285 pharmaceutical executives to leave 28 heavyweight executives in 2020 (attached list)

To some extent, the flow of talent is not only a barometer of the development of pharmaceutical companies themselves, but also a new direction of industry development.
, according to Sina Pharmaceuticals incomplete statistics, in 2020, a total of 285 senior executives in the pharmaceutical industry left.
for panoramic scanning this year's pharmaceutical industry talent flow characteristics, we around this list, respectively, from the separation of posts, reasons for separation, personnel turbulence is relatively large enterprises and other directions to make inventory analysis.
, the departure of 28 heavyweights as the backbone of the fate of a business development, any wind and grass personnel changes can arouse strong concern.
statistics, a total of 28 presidents and chairman-level executives of the pharmaceutical industry will leave their positions in 2020.
From the summary list, "personal reasons" or "work adjustment" have become the usual reasons for the personnel changes of these managers, but on closer analysis, we can see that there are also some managers for special reasons had to leave, such as performance back pot or was investigated or even in jail.
From the whole list, in addition to the list of multinational pharmaceutical executives, local enterprises, Fosun Pharma's former chairman Chen Qiyu, Dong'a Collagen President Qin Yufeng, Fuhong Hanxuan's former CEO Liu Shigao, Ping An good doctor Wang Tao and other prominent people in the industry have attracted attention.
and one of the most unexpected "melons" was Zhang Fangliang, the former chief executive of Kingsley.
August 2020, Kingsley announced that Mr. Zhang had stepped down as chief executive officer of Kingsley, but remained chairman of Kingsley's board of directors and chief executive of legendary bio-subsidiaries.
perhaps originally this was only a personnel transfer out of corporate strategy, did not expect that on the evening of November 22 this year, Zhang Fangliang was arrested for "suspected smuggling of goods prohibited by Chinese law import and export regulations."
2. Over the years, the departure list of multinational pharmaceutical executives in the pharmaceutical industry has been the focus of the industry, according to Sina Pharmaceutical incomplete statistics, this year, a total of 17 multinational pharmaceutical executives in the pharmaceutical industry have under-changed.
Among the most frequently changed were Wang Hong, Vice President and Commercial Officer of the Sales Marketing and Commerce Department of Yuanling North China, and on August 31, 2020, GSK announced that Wang Hong, Vice President of GSK and Head of The Respiratory Business Department, had decided to leave his post for personal reasons.
less than eight months before Wang Hong took over the post, GSK China announced on January 13, 2020 that it had appointed Wang Hong vice president and head of its breathing business.
in addition to Wang Hong, the departure of former Novarma Pharmaceuticals Asia Pacific, Middle East and Africa Regional President and Novarce Group China President Yu Xudong, former Gilead Global Vice President and General Manager of China Luo Yongqing, former GE Senior Vice President, President and CEO of International Business Duan Xiaoxuan, and the departure of former Moshadong China Oncology Division Head Mu Yanping and other executives have also been the focus.
industry analysis, multinational pharmaceutical companies are now frequently "departure tide" may be by the domestic pharmaceutical market drastic changes, the industry reshuffle intensified related.
health care negotiations and drug collection to promote drug prices, China's policy to promote innovative drug research and development frequently, multinational pharmaceutical companies in the past patent dividends no longer, have large-scale adjustment of strategy in China.
, the flow of executives with an international perspective has accelerated, as china's domestic pharmaceutical companies have grown and need a large number of experienced executives to take the road.
3, a number of pharmaceutical companies personnel shocks according to statistics, in this year's personnel turmoil enterprises the biggest changes are Sapp Ais (12), Fosun Pharma (11, including Fuhong Hanxuan Liu Shigao) and Kangmei Pharmaceuticals (11) and Dong A gum (7), and these four enterprises are from the head to the executive collective blood change.
among them, industry analysis, East A gum is mainly due to weak performance, from the beginning of 2020, Dong A gum director and president Qin Yufeng left, after which the financial director, assistant president, vice president Zhou have left.
's 2020 is even more difficult after its first loss in 2019.
October 30, the company announced that operating income fell 27.9% year-on-year from January to September 2020, with a net profit loss of 20.98 million yuan.
, the capital markets don't buy it.
on the day the three-quarter trailer was released, the stock price of Dong'a Gum fell sharply and has fluctuated since then.
, which was once like a cloud of Fosun Pharma, this year's executive blood change also surprised the industry! But apart from widespread industry speculation that Fosun Pharma's wave of executive departures has been affected by poor performance, some of them have been moved internally.
the personnel turmoil between Sapp Ace and Comey Pharmaceuticals was due to the follow-up effects of the Black Swan incident.
In 2017, an article pushed the production of pythonine eye drops (commodity name: Sapp Ace) produced by Zhejiang Shapps Pharmaceutical Co., Ltd. to the forefront, the article questioned the effectiveness of its products, the incident quickly spread on the Internet, affected by public opinion, Shapps Ess enterprise development was greatly affected.
in pursuit of new development, from May 2020, Sapp Ace welcomed "Shanghai Health and Investment Management Co., Ltd." (hereinafter referred to as "Funding and Investment").
change of the actual controller, Sapp Ais executives changed large-scale, is this year's highest number of executive departures of pharmaceutical companies, the number of departures as high as 12 people, including founder and chairman Chen Dekang, general manager Wang Youkun and others.
and Comey's executive purge was thred by a wave of financial fraud that erupted at the end of 2019.
it is understood that Kangmei since this year from the founder Ma Xingtian was taken coercive measures, his brother Ma Xinggu took over as chairman, but soon Ma Xinggu announced his resignation.
it is worth mentioning that Kangmei Pharmaceuticals this year by the Guangzhou Pharmaceutical Group with state-owned" take over, taking over the position of general manager of Ma Xinggu Liu Guowei also has a clear background in the Broad Medicine Department.
. 4, the characteristics of the exit of professionals from the list of departing executives inventory, we also found that in the emerging biopharmaceers continue to develop, experienced research and development leaders, finance leaders become the industry's new hot talent flow.
Cai Dongchen, chairman of Shipharma Group, said in a public statement that the cost of talent in the pharmaceutical industry is getting higher and higher as Hong Kong stocks and companies open their floodgates to unprofitable biopharmaceutical companies and diversify other financing channels, and more and more start-ups are digging up high salaries, accelerating the flow of talent.
5. In terms of the time of departure, the average number of senior executives leaving the pharmaceutical industry each month is about 24, with the largest number of executives leaving in July and September, both exceeding 30, while in August, although the same number of departures exceeded 30, but mainly due to the departure of Sapp Ace executives this month accounted for eight seats.
, it is worth noting that in the past December, as a year-end personnel changes frequent period, this year's number of departures is the lowest, the current statistics only seven.
2020 Pharmaceutical Industry Exit Executive List Inventory